Mekinist
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
Erasca Begins Phase III Trial of Naporafenib, Mekinist in NRAS-Mutant Melanoma
The study will explore the combination in melanoma patients who have progressed on treatment with immunotherapy.
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.
Erasca, Novartis Ink Deal to Study Mekinist, Naporafenib Combo in RAS/MAPK-Driven Cancers
Novartis will provide Mekinist for Erasca's SEACRAFT-1 and SEACRAFT-2 trials in RAS Q61X-mutant solid tumors and NRAS-mutant melanoma, respectively.
The radioligand therapy hit roadblocks with supply constraints in early 2023, but a new manufacturing facility has since helped Novartis get back on track.